MONTREAL, Nov. 7, 2023
/CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2)
("Valeo" or the "Company"), a Canadian pharmaceutical
company, today announced that Mr. Richard
Lajoie has joined the Company's Board of Directors and that
Ms. Maureen C. Brennan has retired
from its Board of Directors
"We are pleased to welcome Richard to the Valeo Board of
Directors. His extensive and diverse pharmaceutical industry
experience brings valuable insight and perspective to our Board at
an important time in the Company's growth and corporate
development", said Richard MacKay,
Chairman. "We would also like to thank Maureen for her 5 years of
dedication, contribution and guidance to our Board of Directors
during a period of transformational growth as Valeo developed into
a leading Canadian pharmaceutical company".
More about Richard Lajoie
Richard Lajoie has been
recognized over the last 24 years as an inspirational and creative
leader with a strong capacity to build high performing teams.
Richard was President of Bausch Health, Canada from 2017 to 2021 before being promoted
to President Ortho Dermatologics US based in New Jersey. He has led innovative business
model transformations, many new launches and completed successful
business development deals.
Prior to Bausch Health, Richard spent 12 years with Novartis
Pharmaceuticals in roles of increasing responsibility (Sales,
Marketing, Government Affairs and Medical) located in Montreal, Calgary and Copenhagen where he led Denmark, Norway and Iceland as General Manager for Novartis
Oncology.
About Valeo Pharma Inc.
Valeo Pharma is a fast-growing Canadian pharmaceutical company
dedicated to the commercialization of innovative prescription
products in Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.